The initial findings from DiaGenic sponsored prospective European multicenter Parkinson study is reported. The initial read out of the first subcohort of 79 PD patients and 75 matched healthy controls with no neurodegenerative disease, shows a diagnostic accuracy of 85% in early disease patients while overall accuracy was 88% across all stages.

The preliminary results of the biomarker development program in Parkinsons’s Disease (PD) were presented at the 19th World Congress on Parkinson’s Disease and Related Disorders in Shanghai in November last year. DiaGenic reported that their gene expression data contained information that can be used to classify PD with high average accuracy in peripheral blood.

The company today reports that further analysis of gene expression data from the whole genome study of the initial cohort has demonstrated a model accuracy of 88% (89% sensitivity and 87% specificity) using a set of around 700 probes. In the clinically important group of early PD,...